. Correction to "Benefit of Axicabtagene Ciloleucel Versus Chemoimmunotherapy in Older Patients and/or Patients With Poor ECOG Performance Status With Relapsed or Refractory Large B-Cell Lymphoma After 2 or More Lines of Prior Therapy". Am J Hematol 2024 Dec 12. doi: 10.1002/ajh.27551.
PMID: 39665297